Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Novartis and Medicines for Malaria Venture Announce Decision to Move to Phase 3 Study for Novel Ganaplacide/lumefantrine-SDF Combination in Adults and Children With Malaria

By Charles Gross
Today, 12:40 PM
As the threat of resistance to current malaria treatments grows1,2, Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

NVS

Read More
1 minute read

Novartis Announced Investigational Oral Monotherapy Iptacopan Demonstrates Clinically Meaningful Superiority over Anti-C5 Treatment in Phase III APPLY-PNH sStudy

By Charles Gross
Today, 12:40 PM
Novartis today announced the pivotal Phase III APPLY-PNH trial met its two primary endpoints, showing investigational oral monotherapy iptacopan was superior to anti-C5 therapies (eculizumab or ravulizumab) in adults with paroxysmal nocturnal hemoglobinuria (PNH) experiencing residual anemia despite prior treatment with anti-C5s1.

NVS